All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is an independent medical education platform. This activity is supported by an educational grant from Lilly. Funders are allowed no direct influence on our content.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View psoriasis and psoriatic arthritis content recommended for you
UK MHRA approves icotrokinra for patients with moderate-to-severe plaque PsO
On October 23, 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved icotrokinra hydrochloride for the treatment of patients with moderate-to-severe plaque psoriasis (PsO) who are aged ≥12 years, weigh ≥40 kg, and are candidates for systemic therapy.1
This approval was supported by results from four phase III clinical trials evaluating icotrokinra in 2,500 patients with moderate-to-severe plaque PsO, including 72 patients aged 12 to <18 years who weigh ≥40 kg.1 At Week 16, icotrokinra hydrochloride demonstrated superior efficacy to placebo in all four trials.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
